-
Isochlorogenic Acid A Targets RIP3 in Cardiac Hypertrophy
2026-09-23
A 2026 Cellular Signalling study identifies isochlorogenic acid A as a regulator of pathological cardiac hypertrophy that acts through RIP3 and downstream CaMKII signaling. Using angiotensin II and transverse aortic constriction models, the authors show that RIP3 contributes to hypertrophy independently of MLKL, providing a mechanistic basis for investigating the RIP3/CaMKII axis in cardiovascular disease research.
-
Estradiol Benzoate: ERα Assay Workflow
2026-09-22
Build more reproducible estrogen receptor alpha assays with a defined organic-solvent stock, controlled vehicle exposure, and orthogonal binding and cellular readouts. This guide connects Estradiol Benzoate use in receptor pharmacology with structure-guided screening logic while clearly separating established product data from practical optimization recommendations.
-
Ertugliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2026-09-22
The VERTIS CV trial established that ertugliflozin was noninferior to placebo for major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Its design separates cardiovascular safety from evidence of superiority, while secondary heart-failure and renal findings provide important context for interpreting SGLT2 inhibitor outcomes.
-
Alda 1 for ALDH2 Cardiac Research
2026-09-21
Alda 1 is an ALDH2 activator for connecting aldehyde detoxification with cardiomyocyte proliferation, pressure-overload studies, and genotype-aware enzyme assays. This practical guide translates recent mouse findings into reproducible biochemical and cell-based workflows while separating established evidence from exploratory applications.
-
Telmisartan in Cardiac Hypertrophy Research
2026-09-21
Telmisartan provides an upstream AT1-receptor control for separating angiotensin II-driven hypertrophy from downstream RIP3/CaMKII mechanisms. This article presents practical dosing, signaling, imaging, and troubleshooting workflows for cardiovascular disease research.
-
Gastrodin, AT1 Signaling, and Reactive Astrocytes
2026-09-20
The reference study used a microglia-conditioned medium model to show that gastrodin reshapes renin–angiotensin system, SIRT3, inflammatory, and neurotrophic responses in reactive astrocytes. Pharmacological inhibition with Azilsartan supported an AT1-linked contribution to astrocyte phenotype changes, while the cellular design also highlights important limits for translating these findings beyond in vitro neuroinflammation models.
-
Fosinopril sodium: Applied ACE Inhibitor Workflows
2026-09-19
Fosinopril sodium supports mechanistic ACE inhibition studies, hypertension research, and translational cardiovascular disease models with a distinctive phosphinic acid scaffold and prodrug pharmacology. This guide pairs assay-ready preparation steps with renal hemodynamics workflows and practical troubleshooting for reproducible results.
-
Anlotinib Hydrochloride: Assay Logic
2026-09-19
Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor whose anti-angiogenic phenotype is best understood through linked target-engagement, endothelial, and translational assays. This guide converts preclinical evidence into a decision framework for rigorous cancer research without confusing pathway inhibition with nonspecific cytotoxicity.
-
AZD0156: ATM Kinase Inhibitor Workflow Guide
2026-09-18
Build more informative DNA damage response experiments with AZD0156 by combining ATM target engagement, double-strand break assays, and functional combination testing. This workflow distinguishes direct pathway inhibition from nonspecific cytotoxicity and supports biomarker-led cancer therapy research.
-
COX-2 Controls Muscle Ischemia After Venom Injury
2026-09-17
A Microvascular Research study identifies a time-dependent role for cyclooxygenase-2 in Bothrops asper venom-induced muscle injury. Lumiracoxib-associated early pathway inhibition worsened acute ischemia but was linked to stronger later VEGF, CD31, and MMP responses, clarifying how COX-2 can be vascularly protective at one stage and restraining of revascularization at another.
-
Hyperthermia–Cisplatin Activates Caspase-8
2026-09-17
The reference study identifies caspase-8 accumulation and activation as a mechanistic link between hyperthermia and cisplatin-enhanced apoptosis and pyroptosis. Its combination of ubiquitination analysis, genetic perturbation, biochemical assays, and ultrastructural imaging provides a framework for interpreting caspase-8-dependent cell death rather than treating caspase activation as a single endpoint.
-
Telmisartan for Reliable Cardiac Assays
2026-09-17
This scenario-driven guide explains how Telmisartan (SKU A8531) can strengthen angiotensin II cardiac hypertrophy, viability, and cytotoxicity workflows. It covers DMSO formulation, assay controls, dose planning, orthogonal readouts, and practical vendor-selection criteria for cardiovascular disease research.
-
Targeted SPP1 Inhibition Reprograms TAMs
2026-09-16
The reference study introduces a phenotypic screening strategy to identify small molecules that reduce SPP1 expression in tumor-associated macrophages, then incorporates promising hits into a TAM-avid polymeric nanoconstruct. Its lead formulation, CANDI460, lowered SPP1 in vitro and in vivo and produced tumor remissions across murine models, providing a framework for macrophage-directed cancer immunotherapy.
-
Angiotensin II: From GPCR Signal to Vascular Insight
2026-09-15
A translational framework for using Angiotensin II to connect GPCR signaling with endothelial dysfunction, vascular remodeling, hypertension mechanisms, and abdominal aortic aneurysm models.
-
Azilsartan: A Causal RAS Assay Framework
2026-09-15
Azilsartan (TAK-536) enables receptor-level interrogation of angiotensin II signaling in cardiovascular and neuroinflammation models. This article translates a reactive astrocyte–microglia study into a rigorous assay framework focused on causal interpretation, controls, and reproducibility.